In 2003, some analogues of FAA were designed and tested as inhibitors of aminopeptidase N (APN/CD13), overexpressed in some tumours, located in both human and murine endothelial vasculature but not in normal vessels. The gene discussed is ANPEP; the disease is neoplasm.